Hematologic Malignancies Panel

Hematologic Malignancies Panel: Precision Decoding of Genetic Keys in Blood Cancers

The Hematologic Malignancies Panel is a series of NGS-based genetic testing solutions, focused on molecular typing, biological significance assessment, and research guidance for hematologic malignancies. The Panel comprehensively covers clinically relevant genetic mutations (SNV/Indel/CNV/Fusion, etc.), enabling comprehensive molecular research on diseases such as Leukemia, Lymphoma, and Myeloma. Its applications span from initial disease subtyping to MRD monitoring.

Key Features:

Myeloblast precursor cells developing into granulocytes.

Integrated Dual-Omics Approach: Proprietary DNA + RNA dual-workflow design overcomes the limitations of single-omics analysis. It simultaneously detects point mutations, fusions, CNVs, and complex structural variants, enabling comprehensive variant profiling.
Exceptional Performance: Ultra-uniform coverage and low background noise ensure the precise detection of low-frequency mutations, meeting the requirements of high-sensitivity studies.
Flexible Customization: Supports splitting by gene subsets or custom target expansion, adapting to specific research.

Request a Quote

Efficient and Focused Hematologic Oncology Research Solution

Expert-defined targeted NGS panels for myeloid leukemia, lymphoma, and other hematologic malignancies concentrate on core disease-associated genes, significantly reducing sequencing costs and data analysis burden. Their rapid, standardized workflow offers high scalability, enabling the efficient simultaneous analysis of hundreds of samples and maximizing research throughput.

Looking for Cancer Clues in the Blood steam

For 50% of myeloid patients with normal cytogenetics, NGS testing addresses diagnostic gaps by detecting additional actionable mutations and identifying novel biomarkers. Integrating key prognostic genes from WHO/NCCN guidelines enables analysis-oriented evaluation and refines disease stratification. This approach facilitates target screening through mutational profiling, matches patients to trial eligibility, and accelerates biomarker-driven drug development.

Why chose CD Genomics

Comprehensive Coverage

We deliver complete hematologic malignancy detection and comprehensive variant analysis.

Optimized Cost-Efficiency

Our Advanced Biosynthesis Technologies reduce costs while maximizing efficiency.

Scalable & Customizable Solutions

Build upon our proven, ready-to-use panels to seamlessly add targeted genes/regions, or design entirely new panels focused on your specific targets of interest.

* For research purposes only, not intended for clinical diagnosis, treatment, or individual health assessments.

CDCap™ Solid Tumor HotSpot Panel Kit
Select options

CDCap™ Human HLA Panel Kit
Select options

CD Respiratory Pathogen Detection Panel Kit
Select options

CD Respiratory Bacteria Detection Panel Kit
Select options

CDCAP 200 Respiratory Pathogen Panel Kit
Select options

CDCAP Respiratory Virus Panel Kit
Select options

CDAMP Respiratory Virus Panel Kit
Select options

CD® HBV Detection Panel Kit
Select options

CD® EBV Detection Panel Kit
Select options

Explore Our Hematologic Malignancies Panel:

Cat. No.	Product Name	Brief Description
PNO010	CDCap™ Hema-Tumor Expanded Gene Panel Kit	CDCap™ Hema-Tumor Expanded Gene Panel utilizes dual-omics hybridization capture to detect SNVs, Indels, CNVs, and fusions across 481 genes in hematologic malignancies. Combines DNA (436 genes + 12 intronic) and RNA (146 genes) workflows for comprehensive genomic profiling.
PNO011	CDCap™ AML MRD Panel Kit	CDCap™ AML MRD Panel Kit is Designed for adult AML MRD research using hybridization capture NGS. Targets 32 genes to sensitively detect SNVs, Indels, and Fusions in blood/bone marrow samples.
PNO012	CDAmp™ Myeloid Neoplasms Panel Kit	CDAmp™ Myeloid Neoplasms Panel uses multiplex PCR-based targeted resequencing to detect SNVs, indels, and ITDs across 58 genes (full CDS in 18 + hotspots in 40) for AML/MDS/MPN research.